Cargando…
Aflibercept Intervention in Experimental Branch Retinal Vein Occlusion Results in Upregulation of DnaJ Homolog Subfamily C Member 17
Aflibercept is an inhibitor of vascular endothelial growth factor (VEGF) used to treat macular edema following branch retinal vein occlusion (BRVO). Despite well-documented efficacy, there is limited knowledge about proteome changes following aflibercept intervention in BRVO. Proteome changes may pr...
Autores principales: | Cehofski, Lasse Jørgensen, Kruse, Anders, Alsing, Alexander Nørgård, Sejergaard, Benn Falch, Nielsen, Jonas Ellegaard, Pedersen, Shona, Muttuvelu, Danson Vasanthan, Kirkeby, Svend, Honoré, Bent, Vorum, Henrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960061/ https://www.ncbi.nlm.nih.gov/pubmed/33747556 http://dx.doi.org/10.1155/2021/6690260 |
Ejemplares similares
-
Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion
por: Cehofski, Lasse Jørgensen, et al.
Publicado: (2022) -
Intravitreal bevacizumab upregulates transthyretin in experimental branch retinal vein occlusion
por: Cehofski, Lasse Jørgensen, et al.
Publicado: (2018) -
IL-18 and S100A12 Are Upregulated in Experimental Central Retinal Vein Occlusion
por: Cehofski, Lasse Jørgensen, et al.
Publicado: (2018) -
Macular Edema in Central Retinal Vein Occlusion Correlates With Aqueous Fibrinogen Alpha Chain
por: Cehofski, Lasse Jørgensen, et al.
Publicado: (2023) -
Dexamethasone Intravitreal Implant Is Active at the Molecular Level Eight Weeks after Implantation in Experimental Central Retinal Vein Occlusion
por: Cehofski, Lasse Jørgensen, et al.
Publicado: (2022)